NEW YORK (GenomeWeb News) – Asuragen today announced that it has received US Food and Drug Administration clearance of its cGMP manufactured sample collection and cellular RNA preservation device.
The device called RNARetain was first cleared by FDA in 2007 in conjunction with Agendia's MammaPrint breast cancer test.